Similar articles

• Amantadine antagonism of oxotremorine effects.

  Eshel Y, Korczyn AD. Eshel Y, et al. J Neural Transm. 1979;46(1):79-83. doi: 10.1007/BF01243431. J Neural Transm. 1979. PMID: 574156
• Potentiation by naloxone of the anti-oxotremorine effect of L-DOPA.

  Quock RM, Lucas TS. Quock RM, et al. Eur J Pharmacol. 1983 Nov 25;95(3-4):193-8. doi: 10.1016/0014-2999(83)90634-9. Eur J Pharmacol. 1983. PMID: 6653670
• A selective potentiation by naloxone of L-dopa but not atropine suppression of oxotremorine-induced tremor in mice.

  Quock RM, Lucas TS. Quock RM, et al. J Pharm Pharmacol. 1985 Sep;37(9):673-4. doi: 10.1111/j.2042-7158.1985.tb05113.x. J Pharm Pharmacol. 1985. PMID: 2867196
• Oxotremorine-induced cholinergic syndrome: modifications by levodopa and/or oral cytidine diphosphocholine.

  Saligaut C, Daoust M, Chadelaud M, Moore N, Chretien P, Boismare F. Saligaut C, et al. Methods Find Exp Clin Pharmacol. 1985 Jan;7(1):5-8. Methods Find Exp Clin Pharmacol. 1985. PMID: 3990445
• MIF (Pro-Leu-Gly-NH2): failure to affect oxotremorine effects in mice and rats as well as fluphenazine catalepsy or amphetamine hyperactivity in rats.

  Björkman S, Lewander T, Zetterström T. Björkman S, et al. J Pharm Pharmacol. 1980 Apr;32(4):296-7. doi: 10.1111/j.2042-7158.1980.tb12917.x. J Pharm Pharmacol. 1980. PMID: 6103063 No abstract available.